Lba18 impact of transient androgen deprivation therapy (adt) with leuprorelin lp 11.25 mg on the histological progression of indolent prostate cancer (pc)–results of a phase iii trial versus active surveillance (as)impact of transient androgen deprivation therapy (adt) with leuprorelin lp 11.25 mg on the histological progression of indolent prostate cancer (pc)–results of a phase iii trial versus active surveillance (as)